GSE207301 A genome-wide association study identified the variations nearby TP53BP2 promote HBsAg loss in patients treated with peginterferon alfa-2a through enhancing interferon response of hepatocytes [HepAD38]

In this study, we found for the first time that the rs7519753 located at 1q41 was associated with HBsAg loss in CHB patients after interferon treatment. Further functional analysis confirmed that the rs7519753-C genotype was associated with the high expression of TP53BP2 in the liver. In addition, TP53BP2 enhanced the activation of interferon pathway by inhibiting the expression of SOCS1 and SOCS2, thereby enhancing the anti-HBV effect of interferon. The outcome of this study may help us to identify CHB patients who will achieve HBsAg loss before the start of pegylated IFN- α-based therapy and reach functional cure.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research